About Khondrion

Khondrion is a pharmaceutical company focusing on the discovering and development of innovative drugs to treat Mitochondrial disease. read more

About Khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. 

The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.

To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. Khondrion is headquartered in Nijmegen, The Netherlands.

Khondrion Details

  • CEO: Jan Smeitink
  • Affliated department: Pediatrics
  • Researcher: Jan Smeitink
  • Year of incorporation: 2007
Khondrion website


What we do